Current Infectious Disease Reports

, Volume 8, Issue 4, pp 293–300 | Cite as


  • Vincent C. Marconi
  • Hector H. Garcia
  • Joel T. Katz


Since international travel has become widespread, clinicians increasingly have been confronted with the diagnosis of symptomatic and incidental neurocysticercosis. The difficulty with managing this disease lies in its varied clinical presentations. The treatment of neurocysticercosis depends upon anatomic locations, stages of cysts, and overall cyst burden. Despite recent clinical and laboratory advances, experts are divided on many key management questions. This article reviews the pathophysiology and experimental data underlying treatment recommendations for this emerging and complex condition.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Olive JL, Angulo RP: Introduction and general aspects. Panel discussion. Cysticercosis of the ner vous system. J Neurosurg 1962, 19:632–634.PubMedGoogle Scholar
  2. 2.
    Mora C, Rubio R, Vergara I, Toro G: Neurocysticercosis. In Central Nervous System Infections. Edited by Toro G, et al. Santafé de Bogotá: Fondo Educativo Interamericano S.A.; 1978:267–283.Google Scholar
  3. 3.
    Sendler T: Cysticerci cellulosae monographia [dissertation]. Halis; 1843:35, 1 plate.Google Scholar
  4. 4.
    Virchow R: Recherches sur le développement de la trichina spiralis (ce ver devient adulte dans l’intestin du chien). C R Seanc Acad Sci 1859, 49:660–662.Google Scholar
  5. 5.
    Joklik WK, Willett HP, Amos DB, eds: Zinsser’s Microbiology. New York: McGraw-Hill Professional; 1995.Google Scholar
  6. 6.
    Jong EC, McMullen R, eds: Travel & Tropical Medicine Manual, edn 2. Philadelphia: W B Saunders; 1995.Google Scholar
  7. 7.
    White AC Jr.: Neurocysticercosis: a major cause of neurological disease worldwide. Clin Infect Dis 1997, 24:101–113.PubMedGoogle Scholar
  8. 8.
    White AC Jr, Weller PF: Cestodes. In Harrison’s Principles of Internal Medicine, edn 15. Edited by Braunwald E, et al. New York: McGraw-Hill Professional; 2001:1248–1251.Google Scholar
  9. 9.
    Robinson P, White AC, Lewis DE, et al.: Sequential expression of the neuropeptides substance P and somatostatin in granulomas associated with murine cysticercosis. Infect Immun 2002, 70:4534–4538.PubMedCrossRefGoogle Scholar
  10. 10.
    Sarti E, Schantz PM, Plancarte A, et al.: Prevalence and risk factors for Taenia solium, taeniasis and cysticercosis in humans and pigs in a village in Morelos, Mexico. Am J Trop Med Hyg 1992, 46:677–679.PubMedGoogle Scholar
  11. 11.
    Garcia HH, Del Brutto OH: Taenia solium cysticercosis. Infect Dis Clin North Am 2000, 14:97–119.PubMedCrossRefGoogle Scholar
  12. 12.
    Schantz PM, Moore AC, Munoz JL, et al.: Neurocysticercosis in an Orthodox Jewish community in New York City. N Engl J Med 1992, 327:692–695.PubMedCrossRefGoogle Scholar
  13. 13.
    Cao W, van der Ploeg CP, Xu J, et al.: Risk factors for human cysticercosis morbidity: a population-based case-control study. Epidemiol Infect 1997, 119:231–235.PubMedCrossRefGoogle Scholar
  14. 14.
    Salgado P, Rojas R, Sotelo J: Cysticercosis. Clinical classification based on imaging studies. Arch Intern Med 1997, 157:1991–1997. A proposed classification system of cysticercosis based on clinical condition, radiographic imaging (eg, MRI), and immunodiagnostic techniques in order to better design individualized therapeutic approaches.PubMedCrossRefGoogle Scholar
  15. 15.
    King CH: Cestodes [tapeworms]. In Bennett’s Principles & Practice of Infectious Diseases, vol 2, edn 5. Edited by Mandell GL, et al. New York: Churchill Livingstone; 2000:2956–2965.Google Scholar
  16. 16.
    Varma A, Gaur KJ: The clinical spectrum of neurocysticercosis in the Uttaranchal region. J Assoc Physicians India 2000, 50:1398–1400.Google Scholar
  17. 17.
    Handle LC, Mervis B: Cerebral cysticercosis with reference to the natural history of parenchymal lesions. AJNR Am J Neuroradiol 1983, 4:709–712.Google Scholar
  18. 18.
    Bustos JA, Garcia HH, Dorregaray R, et al.: Detection of muscle calcifications by thigh CT scan in neurocysticercosis patients. Trans R Soc Trop Med Hyg 2005, 99:775–779.PubMedCrossRefGoogle Scholar
  19. 19.
    Singhi P, Ray M, Singhi S, Khandelwal N: Clinical spectrum of 500 children with neurocysticercosis and response to albendazole therapy. J Child Neurol 2000, 15:207–213.PubMedGoogle Scholar
  20. 20.
    Garcia HH, Del Brutto OH: Imaging findings in neurocysticercosis. Acta Trop 2003, 87:71–78.PubMedGoogle Scholar
  21. 21.
    Scheel CM, Khan A, Hancock K, et al.: Serodiagnosis of neurocysticercosis using synthetic 8-kD proteins: comparison of assay formats. Am J Trop Med Hyg 2005, 73:771–776.PubMedGoogle Scholar
  22. 22.
    Estrada JJ, Kuhn RE: Immunochemical detection of antigens of larval Taenia solium and anti-larval antibodies in the cerebrospinal fluid of patients with neurocysticercosis. J Neurol Sci 1985, 71:39–48.PubMedCrossRefGoogle Scholar
  23. 23.
    Del Brutto OH, Rajshekhar V, White AC Jr, et al.: Proposed diagnostic criteria for neurocysticercosis. Neurology 2001, 57:177–183. Members of the Cysticercosis Working Group of Peru establish diagnostic guidelines and levels of certainty based on clinical, radiographic, and immunologic criteria.PubMedGoogle Scholar
  24. 24.
    Garcia HH, Evans CA, Nash TE, et al.: Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev 2002, 15:747–756.PubMedCrossRefGoogle Scholar
  25. 25.
    Nash TE, Pretell J, Garcia HH.: Calcified cysticerci provoke perilesional edema and seizures. Clin Infect Dis 2001, 33:1649–1653.PubMedCrossRefGoogle Scholar
  26. 26.
    Carpio A, Escobar A, Hauser WA: Cysticercosis and epilepsy: a critical review. Epilepsia 1998, 39:1025–1040.PubMedCrossRefGoogle Scholar
  27. 27.
    Cruz M, Cruz I, Horton J: Albendazole versus praziquantel in the treatment of cerebral cysticercosis: clinical evaluation. Trans R Soc Trop Med Hyg 1991, 85:244–247.PubMedCrossRefGoogle Scholar
  28. 28.
    Takayanagui OM, Jardim E: Therapy for neurocysticercosis. Comparison between albendazole and praziquantel. Arch Neurol 1992, 49:290–294.PubMedGoogle Scholar
  29. 29.
    Sotelo J, del Brutto OH, Penagos P, et al.: Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis. J Neurol 1990, 237:69–72.PubMedCrossRefGoogle Scholar
  30. 30.
    Del Brutto OH, Santibanez R, Noboa CA, et al.: Epilepsy due to neurocysticercosis: analysis of 203 patients. Neurology 1992, 42:389–392.PubMedGoogle Scholar
  31. 31.
    Vazquez V, Sotelo J: The course of seizures after treatment for cerebral cysticercosis. N Engl J Med 1992, 327:696–701.PubMedCrossRefGoogle Scholar
  32. 32.
    Garcia HH, Pretell EJ, Gilman RH, et al.: A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med 2004, 350:249–258. Randomized, blinded trial of 120 patients with seizures and parenchymal cysts who received ABZ and steroids versus placebo, suggesting that antiparasitic therapy is safe and effective, at least in reducing the number of subsequent generalized seizures.PubMedCrossRefGoogle Scholar
  33. 33.
    Singhi P, Dayal D, Khandelwal N: One week versus four weeks of albendazole therapy for neurocysticercosis in children: a randomized, placebo-controlled double blind trial. Pediatr Infect Dis J 2003, 22:268–272.PubMedCrossRefGoogle Scholar
  34. 34.
    Garcia HH, Gilman RH, Horton J, et al.: Albendazole therapy for neurocysticercosis: a prospective doubleblind trial comparing 7 versus 14 days of treatment. Cysticercosis Working Group in Peru. Neurology 1997, 48:1421–1427. This study evaluated the duration of therapy in patients with fewer than 20 intraparenchymal cysts and found no benefit from the longer course.PubMedGoogle Scholar
  35. 35.
    Cruz I, Cruz ME, Carrasco F, Horton J: Neurocysticercosis: optimal dose treatment with albendazole. J Neurol Sci 1995, 133:152–154.PubMedCrossRefGoogle Scholar
  36. 36.
    Bustos JA, Pretell EJ, Llanos-Zavalaga F, et al.: Efficacy of a 3-day course of albendazole treatment in patients with a single neurocysticercosis cyst. Clin Neurol Neurosurg 2006, 108:193–194.PubMedCrossRefGoogle Scholar
  37. 37.
    Palomares F, Palencia G, Ambrosio JR, et al.: Evaluation of the efficacy of albendazole sulphoxide and praziquantel in combination on Taenia crassiceps cysts: in vitro studies. J Antimicrob Chemother 2006, 57:482–488.PubMedCrossRefGoogle Scholar
  38. 38.
    Del Brutto OH, Sotelo J, Roman GC: Therapy for neurocysticercosis: a reappraisal. Clin Infect Dis 1993, 17:730–735.Google Scholar
  39. 39.
    Couldwell WT, Zee CS, Apuzzo ML: Definition of the role of contemporary surgical management in cisternal and parenchymatous cysticercosis cerebri. Neurosurgery 1991, 28:231–237.PubMedCrossRefGoogle Scholar
  40. 40.
    Suastegui Roman RA, Soto-Hernandez JL, Sotelo J: Effects of prednisone on ventriculoperitoneal shunt function in hydrocephalus secondary to cysticercosis: a preliminary study. J Neurosurg 1996, 84:629–633.CrossRefGoogle Scholar
  41. 41.
    Anandh B, Mohanty A, Sampagth S, et al.: Endoscopic approach to intraventricular cysticercal lesions. Minim Invasive Neurosurg 2001, 44:194–196.PubMedCrossRefGoogle Scholar
  42. 42.
    Psarros TG, Zouros A, Coimbra C: Neurocysticercosis: a neurosurgical perspective. South Med J 2003, 96:1019–1022.PubMedCrossRefGoogle Scholar
  43. 43.
    Carpio A, Santillan F, Leon P, et al.: Is the course of neurocysticercosis modified by treatment with antihelminthic agents? Arch Intern Med 1995, 155:1982–1988.PubMedCrossRefGoogle Scholar
  44. 44.
    Singhi P, Jain V, Khandelwal N: Corticosteroids versus albendazole for treatment of single small enhancing computed tomographic lesions in children with neurocysticercosis. J Child Neurol 2004, 19:323–327.PubMedGoogle Scholar
  45. 45.
    Rajshekhar V, Jeyaseelan L: Seizure outcome in patients with a solitary cerebral cysticercus granuloma. Neurology 2004, 62:2236–2240.PubMedGoogle Scholar
  46. 46.
    Bandres J, White AC Jr, Samo T, et al.: Extraparenchymal neurocysticercosis: report of five cases and review of management. Clin Infect Dis 1992, 15:799–811.PubMedGoogle Scholar
  47. 47.
    Proano JV, Madrazo F, Avelar B, et al.: Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med 2001, 345:879–885.PubMedCrossRefGoogle Scholar
  48. 48.
    Garcia HH, Del Brutto OH, Nash TE, et al.: New concepts in the diagnosis and management of neurocysticercosis (Taenia solium). Am J Trop Med Hyg 2005, 72:3–9.PubMedGoogle Scholar
  49. 49.
    Carpio A: Prognosis for seizure recurrence in patients with newly diagnosed neurocysticercosis. Neurology 2002, 59:1730–1734.PubMedGoogle Scholar
  50. 50.
    Garcia HH, Gonzalez AE, Evans CA, et al.: Taenia solium cysticercosis. Lancet 2003, 361:547–556.CrossRefGoogle Scholar
  51. 51.
    Colli BO, Martelli N, Assirati JA Jr, et al.: Results of surgical treatment of neurocysticercosis in 69 cases. J Neurosurg 1986, 65:309–315.PubMedCrossRefGoogle Scholar
  52. 52.
    Gonzalez AE, Gauci CG, Barber D, et al.: Vaccination of pigs to control human neurocysticercosis. Am J Trop Med Hyg 2005, 72:837–839.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  • Vincent C. Marconi
  • Hector H. Garcia
  • Joel T. Katz
    • 1
  1. 1.Medicine Education OfficeBrigham and Women’s HospitalBostonUSA

Personalised recommendations